

how the investigator determined whether zoledronic acid played a role in causing the significant increase in AMI events associated with its use. It should be noted that this study was funded by the manufacturer and that the significant increase in myocardial infarction in the patients receiving the study drug was not mentioned in the article's abstract but rather was buried in the "Safety" section of their article.

An earlier study of a similar regimen of zoledronic acid vs placebo for treatment of postmenopausal osteoporosis found that serious atrial fibrillation occurred more frequently in the zoledronic acid group ($P < .001$).³

Given that we now have at least 3 studies documenting significantly increased rates of adverse cardiac outcomes with the use of bisphosphonates, it may be time to conduct a large randomized clinical trial examining the cardiac safety of bisphosphonate therapy.

David L. Keller, MD
Torrance, CA

Data Previously Presented: Dr Keller writes an ongoing series of comments on PubMed Commons (a blog). The observations made in this letter were previously included in his blog, at the following link: http://www.ncbi.nlm.nih.gov/pubmed/23113482#cm23113482_3697.

1. Pittman CB, Davis LA, Zeringue AL, et al. Myocardial infarction risk among patients with fractures receiving bisphosphonates. *Mayo Clin Proc*. 2014; 89(1):43-51.
2. Boonen S, Reginster JY, Kaufman JM, et al. Fracture risk and zoledronic acid therapy in men with osteoporosis. *N Engl J Med*. 2012;367(18):1714-1723.
3. Black DM, Delmas PD, Eastell R, et al; HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid

for treatment of postmenopausal osteoporosis. *N Engl J Med*. 2007;356(18):1809-1822.

<http://dx.doi.org/10.1016/j.mayocp.2014.04.012>

In reply—Adverse Cardiac Effects of Bisphosphonates

I appreciate Dr Keller's comments and agree with his call for additional research focusing on the cardiovascular effects of bisphosphonate therapy. A prospective clinical study would be a welcome addition to our knowledge base on this topic. Given the association of oral calcium supplementation with myocardial infarction and other cardiovascular events,¹ future studies of bisphosphonates and cardiovascular events should also analyze the effects of oral calcium supplementation. There is a paucity of data on female subjects, and future studies should be designed to include this population.

Bisphosphonates remain a staple of osteoporosis management and a vital tool for fracture prevention. However, the emerging awareness of the association between cardiovascular events and bisphosphonate therapy prompts clinicians to further personalize osteoporosis management. The World Health Organization Fracture Risk Assessment Tool (FRAX)² and the National Osteoporosis Foundation's *Clinician's Guide to Prevention and Treatment of Osteoporosis*,³ which incorporates the FRAX score, are useful aids. They may assist clinicians to minimize unnecessary bisphosphonate exposure in some patients who have low bone mineral density (BMD) but not osteoporosis. (An important caveat is that FRAX is most useful in

patients with a low femoral neck BMD, and it may underestimate fracture risk in patients who have low BMD at the lumbar spine but a relatively normal BMD at the femoral neck.)

Additionally, health care professionals may submit a MedWatch voluntary report⁴ when adverse cardiovascular events occur in patients taking bisphosphonates. Such reports may provide a springboard for increased awareness and for future research on this subject.

Cory B. Pittman, MD

Mercy Arthritis and Osteoporosis Center
Urbandale, IA

1. Bolland MJ, Avenell A, Baron JA, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. *BMJ*. 2010;341:c3691.
2. World Health Organization. FRAX: WHO Fracture Risk Assessment Tool. <http://www.shef.ac.uk/FRAX/tool.aspx>. Accessed April 6, 2014.
3. National Osteoporosis Foundation. *Clinician's Guide to Prevention and Treatment of Osteoporosis*. Washington, DC: National Osteoporosis Foundation; 2013.
4. US Food and Drug Administration. MedWatch Online Voluntary Reporting Form. <https://www.accessdata.fda.gov/scripts/medwatch/>. Accessed April 23, 2014.

<http://dx.doi.org/10.1016/j.mayocp.2014.04.014>

CORRECTION

In the article "Lipoprotein(a), Cardiovascular Disease, and Contemporary Management," published in the November 2013 issue of *Mayo Clinic Proceedings* (2013;88(11):1294-1311), Lp(a) cholesterol and Lp(a)-C should read as Lp(a) throughout the article.

<http://dx.doi.org/10.1016/j.mayocp.2014.06.005>